Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation.
de Arriba de la Fuente F, Durán MS, Álvarez MÁ, Sanromán IL, Dios AM, Ríos Tamayo R, García R, González MS, Prieto E, Bárez A, Escalante F, Tejedor A, Ballesteros M, Cabañas V, Capote FJ, Couto C, Garzón S, González-Pardo M, Mateos Manteca MV. de Arriba de la Fuente F, et al. Among authors: gonzalez pardo m. Semin Hematol. 2018 Oct;55(4):189-196. doi: 10.1053/j.seminhematol.2017.09.002. Epub 2017 Oct 13. Semin Hematol. 2018. PMID: 30502846 Review.
Unravelling Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treatment in Real-World Practice in Spain: The CARINAE Study.
de Arriba de la Fuente F, Gironella Mesa M, Hernández García MT, Soler Campos JA, Herráez Rodríguez S, Moreno Belmonte MJ, Regueiro López T, González-Pardo M, Casanova Espinosa M, On Behalf Of The Carinae Study Investigators. de Arriba de la Fuente F, et al. Among authors: gonzalez pardo m. Pharmaceuticals (Basel). 2024 Sep 26;17(10):1272. doi: 10.3390/ph17101272. Pharmaceuticals (Basel). 2024. PMID: 39458913 Free PMC article.
Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.
Arteche-López A, Kreutzman A, Alegre A, Sanz Martín P, Aguado B, González-Pardo M, Espiño M, Villar LM, García Belmonte D, de la Cámara R, Muñoz-Calleja C. Arteche-López A, et al. Among authors: gonzalez pardo m. Bone Marrow Transplant. 2017 Jun;52(6):832-838. doi: 10.1038/bmt.2017.29. Epub 2017 Apr 3. Bone Marrow Transplant. 2017. PMID: 28368375 Clinical Trial.